ImmunityBio reported early clinical activity for its allogeneic CD19 CAR‑NK therapy in patients with Waldenström’s macroglobulinemia. Company data show durable complete responses in the first four evaluable patients treated with CAR‑NK plus rituximab, with responses sustained through seven and 15 months in two individuals. The regimen was delivered without lymphodepletion in an outpatient setting. The presentation and company update drove a near‑term market move — ImmunityBio shares jumped on the announcement — and the data underpin plans to expand enrollment and follow durability endpoints. The finding highlights the potential of off‑the‑shelf NK platforms to deliver outpatient, repeatable dosing with limited preparative conditioning. Investigators and ImmunityBio plan longer follow‑up and additional cohorts to define safety, confirm response durability, and evaluate broader indications. Sources: company press disclosures and early trial reports presented at investor and conference forums.